Form 4: Director Mark Strome Increases HeartBeam Stake

Director Mark E. Strome acquired 750,000 shares of HeartBeam, Inc. common stock at $0.80 per share.

Summary

• Director Mark E. Strome purchased 750,000 shares of HeartBeam, Inc. (BEAT) common stock.
• The transaction occurred on April 16, 2026, at a price of $0.80 per share.
• The purchase was made in connection with the company's underwritten public offering of 12,500,000 shares.
• Following this transaction, the reporting person beneficially owns 3,650,000 shares held through various entities including Strome Mezzanine Fund II, LP, the Mark E. Strome Living Trust, and Strome Dynasty, LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as significant insider buying during a capital raise often indicates management's belief in the company's valuation and future prospects.

Positives

• Insider confidence is demonstrated by a director purchasing a significant block of 750,000 shares.
• The purchase aligns the director's interests with those of other shareholders following the public offering.

Negatives

• The purchase was part of a public offering, which typically results in dilution for existing shareholders.

Risks

• Market volatility associated with small-cap equity investments.
• Reliance on the success of the company's underwritten public offering to fund operations.

Future Outlook

The filing does not provide specific forward-looking guidance, but notes the completion of a 12,500,000 share public offering.

Management Comments

• Mr. Strome disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider participation in public offerings is generally viewed as a positive signal of long-term conviction in the company's clinical or commercial roadmap.

Comparison to Industry Standards

• Insider buying during public offerings is a common practice in the biotech and medical device sectors to signal support to the market.

Related Party Transactions

• Securities are held by Strome Mezzanine Fund II, LP, Mark E. Strome Living Trust, and Strome Dynasty, LLC, all of which are controlled by the reporting person.

Stakeholder Impact

• Shareholders may view the director's participation as a vote of confidence in the company's recent capital raise.

Next Steps

• Continued monitoring of SEC filings for further insider activity or changes in beneficial ownership.

Key Dates

Recommendation

While insider buying is a positive indicator, the stock is currently undergoing dilution from a recent public offering, suggesting a wait-and-see approach to evaluate how the new capital is deployed.

Keywords

HeartBeam, BEAT, Insider Trading, Form 4, Equity Offering, Director Purchase